This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Lung Cancer Alliance's Long Sought Goal Of A Federal Research Plan Of Action For All Aspects Of The Disease Clears Another Critical Hurdle - Just Approved By United States Senate - One Step Closer To Becoming Law

Recalcitrant Cancer Research Act Creates New NCI Scientific Framework Focused on Lethal Cancers – Lung and Pancreatic to Launch Initiative

WASHINGTON, Nov. 29, 2012 /PRNewswire-USNewswire/ -- Today, Lung Cancer Alliance (LCA) announced that its long sought goal of establishing a research priority within the National Cancer Institute (NCI) on lung cancer was another step closer to becoming law with the United States Senate's approval of the Recalcitrant Cancer Research Act of 2012.     

The legislation is a modified version of the bill formerly known as the Pancreatic Cancer Research & Education Act which passed the House of Representatives September 18, 2012 with strong bi-partisan support.  The Senate passed the legislation as an amendment to the Department of Defense Authorization bill. The Senate must pass the entire bill and the House of Representatives must concur before it can proceed to the President for approval.   

The Recalcitrant Cancer Research Act of 2012 requires NCI to develop comprehensive plans of research action, or scientific frameworks, to address the most lethal cancers – those with a five year survival rate of less than 50 percent. Immediate attention is to be given to lung and pancreatic cancers.

LCA worked closely with the Pancreatic Cancer Action Network to secure priority status for lung and pancreatic cancers in the legislation which together cause one in every three cancer deaths and whose 5-year survival rates of 15% and 6% respectively have barely moved since the 1972 launch of the "War on Cancer".

Laurie Fenton Ambrose, LCA President & CEO, credited the achievement to the unrelenting work of the Pancreatic Cancer Action Network and its advocates along with the extraordinary efforts of lung cancer advocates all across the country who worked tirelessly to shine a brighter light on these deadly cancers. 

In addition, Fenton Ambrose commended Senate leaders, specifically Senator Sheldon Whitehouse for his work on behalf of the pancreatic cancer community and Senators Dianne Feinstein, Johnny Isakson and John Kerry for their sponsorship of the Lung Cancer Mortality Reduction Act whose central tenant, bringing a coordinated and comprehensive research approach to all aspects of the disease, was incorporated in the amended bill. 

"Advocates, committed congressional leaders and legislative momentum were the driving factors that gave LCA the leverage needed to secure priority status for lung cancer in the compromise bill that was negotiated in the House and Senate Health Committees over the past weeks," she said. "Thank you advocates and thank you Senate leaders for helping us realize this long sought goal."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,026.59 -43.81 -0.24%
S&P 500 2,112.66 -1.83 -0.09%
NASDAQ 4,999.8050 -17.1240 -0.34%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs